BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16977630)

  • 1. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
    Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
    Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
    Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.
    Barrou B; Benoît G; Ouldkaci M; Cussenot O; Salcedo M; Agrawal S; Massicard S; Bercovici N; Ericson ML; Thiounn N
    Cancer Immunol Immunother; 2004 May; 53(5):453-60. PubMed ID: 14760510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
    Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
    Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
    Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
    Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
    Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
    Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
    Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
    Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
    Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
    Fay JW; Palucka AK; Paczesny S; Dhodapkar M; Johnston DA; Burkeholder S; Ueno H; Banchereau J
    Cancer Immunol Immunother; 2006 Oct; 55(10):1209-18. PubMed ID: 16331519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.